Compare NYAX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | AGIO |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2022 | 2013 |
| Metric | NYAX | AGIO |
|---|---|---|
| Price | $67.29 | $40.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $49.50 | $38.88 |
| AVG Volume (30 Days) | 10.9K | ★ 1.1M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $30.66 | $76.75 |
| Revenue Next Year | $21.70 | $170.73 |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.17 | $22.24 |
| 52 Week High | $76.86 | $46.00 |
| Indicator | NYAX | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 62.25 |
| Support Level | $62.44 | $39.31 |
| Resistance Level | $68.79 | $43.81 |
| Average True Range (ATR) | 1.98 | 1.67 |
| MACD | -0.04 | -0.35 |
| Stochastic Oscillator | 45.81 | 49.94 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.